Document Detail


Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
MedLine Citation:
PMID:  22875242     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The eosinophil is a multifunctional granulocyte best known for providing host defense against parasites. Paradoxically, eosinophils are also implicated in the pathogenesis of allergic inflammation, asthma, and hypereosinophilic syndromes. Emerging evidence also supports the potential for harnessing the cytotoxic power of eosinophils and redirecting it to kill solid tumors. Central to eosinophil physiology is interleukin-5 (IL-5) and its receptor (IL-5R) which is composed of a ligand-specific alpha chain (IL-5Rα) and the common beta chain (βc). Eosinophil activation can lead to their degranulation, resulting in rapid release of an arsenal of tissue-destructive proinflammatory mediators and cytotoxic proteins that can be both beneficial and detrimental to the host. This review discusses eosinophil immunobiology and therapeutic strategies for targeting of IL-5 and IL-5R, as well as the potential for harnessing eosinophil cytotoxicity as a tumoricide.
Authors:
Zhaleh J Amini-Vaughan; Margarita Martinez-Moczygemba; David P Huston
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current allergy and asthma reports     Volume:  12     ISSN:  1534-6315     ISO Abbreviation:  Curr Allergy Asthma Rep     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-03     Completed Date:  2013-03-29     Revised Date:  2013-10-17    
Medline Journal Info:
Nlm Unique ID:  101096440     Medline TA:  Curr Allergy Asthma Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  402-12     Citation Subset:  IM    
Affiliation:
Department of Microbial and Molecular Pathogenesis, Texas A&M College of Medicine, Clinical Science and Translational Research Institute, Texas A&M Health Science Center, 2121 West Holcombe Boulevard, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma / drug therapy
Churg-Strauss Syndrome / drug therapy
Clinical Trials as Topic
Cytotoxicity, Immunologic*
Dermatitis, Atopic / drug therapy
Eosinophils / immunology*
Humans
Hypereosinophilic Syndrome / drug therapy*,  immunology
Hypersensitivity / drug therapy*,  immunology
Inflammation / drug therapy
Interleukin-5 / antagonists & inhibitors*
Nasal Polyps / drug therapy
Neoplasms / drug therapy*,  immunology
Phosphorothioate Oligonucleotides / therapeutic use
Receptors, Interleukin-5 / antagonists & inhibitors*
Grant Support
ID/Acronym/Agency:
R01 AI036936/AI/NIAID NIH HHS; R01 AI036936/AI/NIAID NIH HHS; R56 AI097372/AI/NIAID NIH HHS; U19 AI071130/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Interleukin-5; 0/Phosphorothioate Oligonucleotides; 0/Receptors, Interleukin-5; 0/TPI ASM8; 0/benralizumab; 0/mepolizumab; 0/reslizumab
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Encapsulation and release of aqueous components from sonochemically produced protein microspheres.
Next Document:  Patient Specific Prostate Segmentation in 3D Magnetic Resonance Images.